Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

JPMorgan Diversified Return International Eqty ETFTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

JPMorgan Diversified Return International Eqty ETF vs State Street SPDR S&P Biotech ETF — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $77, while State Street SPDR S&P Biotech ETF trades at $159.35. Which is the better fit depends on your goals.

JPINXBI
52-Week High
$77.00$164.28
52-Week Low
$64.96$86.92
Sector
Broad Market / Factor

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Diversified Return International Eqty ETF

JPIN trades at $76.515, up 0.2% today, with technical indicators signaling a bullish trend from moving averages but caution from overbought RSI levels. The ETF, launched in 2014, provides exposure to foreign large-cap value stocks, with a dividend scheduled for June 2026. Recent news highlights its smart beta strategy and broad market category focus.

The outlook remains positive due to strong technical momentum and diversified international equity exposure, though overbought conditions and reliance on global markets pose risks. Investors benefit from value-oriented strategies but should monitor international economic volatility for potential impacts on performance.

State Street SPDR S&P Biotech ETF

XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.

Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.

Returns comparison

Trailing returns across standard periods

About JPMorgan Diversified Return International Eqty ETF

The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.

Read more on JPIN

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI